Literature DB >> 16621916

Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients.

Naoki Atsuta1, Hirohisa Watanabe, Mizuki Ito, Haruhiko Banno, Keisuke Suzuki, Masahisa Katsuno, Fumiaki Tanaka, Akiko Tamakoshi, Gen Sobue.   

Abstract

Spinal and bulbar muscular atrophy (SBMA) is an adult-onset motoneuron disease caused by a CAG-repeat expansion in the androgen receptor (AR) gene and for which no curative therapy exists. However, since recent research may provide opportunities for medical treatment, information concerning the natural history of SBMA would be beneficial in planning future clinical trials. We investigated the natural course of SBMA as assessed by nine activities of daily living (ADL) milestones in 223 Japanese SBMA patients (mean age at data collection = 55.2 years; range = 30-87 years) followed from 1 to 20 years. All the patients were diagnosed by genetic analysis. Hand tremor was an early event that was noticed at a median age of 33 years. Muscular weakness occurred predominantly in the lower limbs, and was noticed at a median age of 44 years, followed by the requirement of a handrail to ascend stairs at 49, dysarthria at 50, dysphagia at 54, use of a cane at 59 and a wheelchair at 61 years. Twenty-one of the patients developed pneumonia at a median age of 62 and 15 of them died at a median age of 65 years. The most common cause of death in these cases was pneumonia and respiratory failure. The ages at onset of each ADL milestone were strongly correlated with the length of CAG repeats in the AR gene. However CAG-repeat length did not correlate with the time intervals between each ADL milestone, suggesting that although the onset age of each ADL milestone depends on the CAG-repeat length in the AR gene, the rate of disease progression does not. The levels of serum testosterone, an important triggering factor for polyglutamine-mediated motoneuron degeneration, were maintained at relatively high levels even at advanced ages. These results provide beneficial information for future clinical therapeutic trials, although further detailed prospective studies are also needed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16621916     DOI: 10.1093/brain/awl096

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  73 in total

1.  Difference in chronological changes of outcome measures between untreated and placebo-treated patients of spinal and bulbar muscular atrophy.

Authors:  Atsushi Hashizume; Masahisa Katsuno; Haruhiko Banno; Keisuke Suzuki; Noriaki Suga; Fumiaki Tanaka; Gen Sobue
Journal:  J Neurol       Date:  2011-09-28       Impact factor: 4.849

Review 2.  Onset Manifestations of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease).

Authors:  Josef Finsterer; Gianni Soraru
Journal:  J Mol Neurosci       Date:  2015-10-19       Impact factor: 3.444

Review 3.  Genetic approaches to the treatment of inherited neuromuscular diseases.

Authors:  Bhavya Ravi; Anthony Antonellis; Charlotte J Sumner; Andrew P Lieberman
Journal:  Hum Mol Genet       Date:  2019-10-01       Impact factor: 6.150

4.  Quinine-responsive muscle cramps in X-linked bulbospinal muscular atrophy Kennedy.

Authors:  J Finsterer; C Stöllberger
Journal:  J Neurol       Date:  2009-03-22       Impact factor: 4.849

5.  A functional scale for spinal and bulbar muscular atrophy: Cross-sectional and longitudinal study.

Authors:  Atsushi Hashizume; Masahisa Katsuno; Keisuke Suzuki; Haruhiko Banno; Noriaki Suga; Tomoo Mano; Amane Araki; Yasuhiro Hijikata; Christopher Grunseich; Angela Kokkinis; Akihiro Hirakawa; Hirohisa Watanabe; Masahiko Yamamoto; Kenneth H Fischbeck; Gen Sobue
Journal:  Neuromuscul Disord       Date:  2015-03-20       Impact factor: 4.296

Review 6.  Clinical Trials in Spinal and Bulbar Muscular Atrophy-Past, Present, and Future.

Authors:  Patrick Weydt; Anna Sagnelli; Angela Rosenbohm; Pietro Fratta; Pierre-François Pradat; Albert C Ludolph; Davide Pareyson
Journal:  J Mol Neurosci       Date:  2015-11-14       Impact factor: 3.444

Review 7.  The Role of the Protein Quality Control System in SBMA.

Authors:  Paola Rusmini; Valeria Crippa; Riccardo Cristofani; Carlo Rinaldi; Maria Elena Cicardi; Mariarita Galbiati; Serena Carra; Bilal Malik; Linda Greensmith; Angelo Poletti
Journal:  J Mol Neurosci       Date:  2015-11-14       Impact factor: 3.444

Review 8.  Diagnostic Clinical, Electrodiagnostic and Muscle Pathology Features of Spinal and Bulbar Muscular Atrophy.

Authors:  Manu E Jokela; Bjarne Udd
Journal:  J Mol Neurosci       Date:  2015-11-16       Impact factor: 3.444

Review 9.  Neuropathology and therapeutic intervention in spinal and bulbar muscular atrophy.

Authors:  Haruhiko Banno; Masahisa Katsuno; Keisuke Suzuki; Fumiaki Tanaka; Gen Sobue
Journal:  Int J Mol Sci       Date:  2009-03-10       Impact factor: 5.923

10.  Nucleation of protein aggregation kinetics as a basis for genotype-phenotype correlations in polyglutamine diseases.

Authors:  Keizo Sugaya; Shiro Matsubara
Journal:  Mol Neurodegener       Date:  2009-07-15       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.